Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe

Year to date, shares of Intra-Cellular have gained 6.9% against the industry's 5.8% decline. Please note that the company is simultaneously evaluating lumateperone for several other indications. The most prominent of the additional indications being pursued for the drug is major depressive disorder (MDD). In the first half of 2024, the company reported achieving the primary and key secondary efficacy endpoints in two global phase III studies, 501 and 502, evaluating 42 mg of lumateperone as an adjunctive th ...